Overcoming the Lack of Oral Availability of Cyclic Hexapeptides: Design of a Selective and Orally Available Ligand for the Integrin αvβ3.

Overcoming the Lack of Oral Availability of Cyclic Hexapeptides: Design of a Selective and Orally Available Ligand for the Integrin αvβ3.
复制标题

克服环状六肽口服可用性的不足:整合素âαvÎ23的选择性口服配体的设计

DOI:
10.1002/anie.201709709
复制
发表时间:
2017
期刊:
影响因子:
--
通讯作者:
H. Kessler
H. Kessler
中科院分区:
--
文献类型:
--
作者:
M. Weinmüller;F. Rechenmacher;U. Kiran Marelli;F. Reichart;T. G. Kapp;A. F. B. Räder;F. S. Di Leva;L. Marinelli;E. Novellino;J. M. Muñoz-Félix;K. Hodivala-Dilke;A. Schumacher;J. Fanous;C. Gilon;A. Hoffman;H. Kessler

文献摘要

参考文献

被引文献

相似文献

开发口服生物可利用和生物活性环状N-甲基化六肽作为整联蛋白αvβ3的高亲和力配体的高度系统性方法基于两个概念:a)筛选具有空间多样性的系统设计文库和B)用亲脂性保护基团掩蔽肽电荷。   该方法的关键步骤是1)初始设计茎肽环(d-Ala-Ala 5)的N-甲基化类似物的组合文库; 2)选择具有最高肠渗透性的环肽; 3)设计在所有可能位置具有生物活性RGD序列的子文库; 4)选择识别RGD的整合素亚型的最佳配体; 5)通过额外的Ala至Xaa取代微调亲和力和选择性; 6)根据前药概念保护带电官能团以恢复肠和口腔渗透性; 7)经口给药后在小鼠中的生物学效应证明。       
A highly systematic approach for the development of both orally bioavailable and bioactive cyclic N‐methylated hexapeptides as high affinity ligands for the integrin αvβ3 is based on two concepts: a) screening of systematically designed libraries with spatial diversity and b) masking of the peptide charge with a lipophilic protecting group. The key steps of the method are 1) initial design of a combinatorial library of N‐methylated analogues of the stem peptide cyclo(d‐Ala‐Ala5); 2) selection of cyclic peptides with the highest intestinal permeability; 3) design of sublibraries with the bioactive RGD sequence in all possible positions; 4) selection of the best ligands for RGD‐recognizing integrin subtypes; 5) fine‐tuning of the affinity and selectivity by additional Ala to Xaa substitutions; 6) protection of the charged functional groups according to the prodrug concept to regain intestinal and oral permeability; 7) proof of biological effects in mice after oral administration.
DOI: 10.1021/ja303200d
发表时间: 2012-07-25
影响因子: 15
作者:
Beck, Johannes G.;Chatterjee, Jayanta;Kessler, Horst
通讯作者: Kessler, Horst
立体异构体肽库和模拟肽设计,用于神经性 Krebstherapie 的 αv β3 整合素选择性抑制剂
DOI: 10.1002/ange.19971091304
发表时间: 1997
期刊: Angewandte Chemie
影响因子: --
作者:
R. Haubner;I. Kessler
通讯作者: I. Kessler
DOI: 10.1002/chem.201501270
发表时间: 2015-05-26
影响因子: 4.3
作者:
Marelli, Udaya Kiran;Bezencon, Jacqueline;Kessler, Horst
通讯作者: Kessler, Horst
DOI: 10.2174/187152010794728639
发表时间: 2010-12
影响因子: 2.8
作者:
Mas-Moruno C;Rechenmacher F;Kessler H
通讯作者: Kessler H
DOI: 10.1021/cb300515u
发表时间: 2013-03-15
影响因子: 4
作者:
Bock JE;Gavenonis J;Kritzer JA
通讯作者: Kritzer JA